Interim Analyses LANREL07484: Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumors Treated with Lanreotide Autogel in South Africa

#2062

Introduction: LANRELO7484 is an ongoing, observational study in patients with symptomatic gastroenteropancreatic neuroendocrine tumours (GEP-NET) in South Africa (SA).

Aim(s): The study aims to evaluate patients’ level of satisfaction and symptomatic response with diarrhoea and/or flushing when treated with Lanreotide Autogel over a six-month period. Quality of life (QoL), exposure to treatment and safety of Lanreotide Autogel in patients with GEP-NET treated with Lanreotide Autogel are also being measured.

Materials and methods: This is a national, ongoing, multi-centre, prospective observational cohort study involving 11 oncology sites. The decision on treatment is made in accordance with routine clinical practice at the centre concerned. Patients are followed up for 6 months after commencing treatment with Lanreotide Autogel. The data is collected prospectively at a baseline visit, 3 months (3M) and 6 months (6M). The QoL data reported in this abstract is an interim analysis of the data available on the 7th of August 2017 for 23 patients.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Geldenhuys D

Authors: Geldenhuys D, Jacobs C, Rapoport B, Fourie S, Szpak W,

Keywords: Gastroenteropancreatic Neuroendocrine Tumors, Quality of Life,